

9/15/2005 IDS

EXPRESS MAIL NO.: EV 531 712 866 US

JCI7/10/03 PCT/PTO 15 SEP 2005

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

11340-007-999

APPLICATION NO. 10/349958  
To Be Assigned  
(National Stage of  
PCT/EP02/04303, filed  
April 18, 2002)

APPLICANT

Ensoli

FILING DATE

On Even Date Herewith

GROUP

To Be Assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,506,555	01/14/03	Andre et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 99/63998	12/16/99	PCT (with English abstract)	abstract only			
	B02	WO 00/33654	06/15/00	PCT				

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Andre et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13120-4.
C02	Berthelot et al. Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxy,3'-thyacytidine [correction of 2',3'-dideoxycytidine] and ritonavir. Arch Dermatol. 1997 Apr;133(4):531.
C03	Conant et al. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS. 1997 Aug;11(10):1300-1.
C04	Sgadari et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002 Mar;8(3):225-32.
C05	International Search Report for International Application No. PCT/EP02/04303.

EXAMINER /Nicole Kinsey/

DATE CONSIDERED

03/26/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NK/

NY/D-1575078.1